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Abstract
Introduction
Plasmodium vivaxmalaria has a wide geographic distribution and poses challenges to
malaria elimination that are likely to be greater than those of P. falciparum. Diagnostic tools
for P. vivax infection in non-reference laboratory settings are limited to microscopy and rapid
diagnostic tests but these are unreliable at low parasitemia. The development and valida-
tion of a high-throughput and sensitive assay for P. vivax is a priority.
Methods
A high-throughput LAMP assay targeting a P. vivaxmitochondrial gene and deploying color-
imetric detection in a 96-well plate format was developed and evaluated in the laboratory.
Diagnostic accuracy was compared against microscopy, antigen detection tests and PCR
and validated in samples from malaria patients and community controls in a district hospital
setting in Sabah, Malaysia.
Results
The high throughput LAMP-P. vivax assay (HtLAMP-Pv) performed with an estimated limit
of detection of 1.4 parasites/ μL. Assay primers demonstrated cross-reactivity with P. know-
lesi but not with other Plasmodium spp. Field testing of HtLAMP-Pv was conducted using
149 samples from symptomatic malaria patients (64 P. vivax, 17 P. falciparum, 56 P. know-
lesi, 7 P.malariae, 1 mixed P. knowlesi/P. vivax, with 4 excluded). When compared against
PLOS Neglected Tropical Diseases | DOI:10.1371/journal.pntd.0004443 February 12, 2016 1 / 16
OPEN ACCESS
Citation: Britton S, Cheng Q, Grigg MJ, Poole CB,
Pasay C, William T, et al. (2016) Sensitive Detection
of Plasmodium vivax Using a High-Throughput,
Colourimetric Loop Mediated Isothermal Amplification
(HtLAMP) Platform: A Potential Novel Tool for Malaria
Elimination. PLoS Negl Trop Dis 10(2): e0004443.
doi:10.1371/journal.pntd.0004443
Editor: Alyssa E. Barry, Walter and Eliza Hall
Institute, AUSTRALIA
Received: October 5, 2015
Accepted: January 18, 2016
Published: February 12, 2016
Copyright: © 2016 Britton et al. This is an open
access article distributed under the terms of the
Creative Commons Attribution License, which permits
unrestricted use, distribution, and reproduction in any
medium, provided the original author and source are
credited.
Data Availability Statement: All relevant data are
within the paper and its Supporting Information files.
Funding: This work was supported by Malaysian
Ministry of Health (Grant #BP00500420), AusAlD
Asia-Pacific Malaria Elimination Network (Grant
#108-07), Australian National Health and Medical
Research Council (Program grant #1037304, Project
Grant #1045156, Practitioner fellowship to NMA
#1042072 and JSM #1041802, scholarship to SB
#1055410 and MJG #1074795), and UK Medical
Research Council (ESEI) (grant #1100796). The
multiplex PCR, HtLAMP-Pv demonstrated a sensitivity for P. vivax of 95% (95% CI 87–
99%); 61/64), and specificity of 100% (95% CI 86–100%); 25/25) when P. knowlesi samples
were excluded. HtLAMP-Pv testing of 112 samples from asymptomatic community controls,
7 of which had submicroscopic P. vivax infections by PCR, showed a sensitivity of 71%
(95% CI 29–96%; 5/7) and specificity of 93% (95% CI87-97%; 98/105).
Conclusion
This novel HtLAMP-P. vivax assay has the potential to be a useful field applicable molecular
diagnostic test for P. vivax infection in elimination settings.
Author Summary
Plasmodium vivax has a worldwide distribution and is the second most common causative
agent of human malaria. The dormant liver stage of P. vivax allows the infection to recur
unless diagnosed and treated appropriately, which poses a significant challenge to the
goals of malaria elimination and eradication as outlined by the WHO. Although highly
sensitive molecular diagnostic tools are available in reference laboratory settings, the cur-
rently available diagnostic tools outside referral settings for the detection of P. vivax are
limited to microscopy and rapid diagnostic tests, which are insufficiently sensitive for the
detection of low level parasitemia particularly in asymptomatic individuals. Based on a
DNA amplification technology called loop-mediated isothermal amplification (LAMP),
this study describes the development and validation of a colourimetric, high throughput
assay (HtLAMP) suitable for the detection of P. vivax infection in non-referral settings.
The sensitivity of the assay combined with its field applicability offers the potential for it to
play an important role as a diagnostic tool for the purpose of malaria elimination.
Introduction
Plasmodium vivax is the most geographically widespread of the Plasmodium species that infect
humans [1] and can cause severe and fatal disease [2]. In the 2014 World Malaria Report it was
estimated that there were 15.8 million cases of P. vivax in 2013, accounting for 47% of malaria
cases outside the African region [3]. Asymptomatic sub-microscopic P. vivax infection is com-
monly reported in endemic countries [4–6], accounting for on average 69.5% of P. vivax infec-
tion relative to those with patent parasitaemias from community surveys [7], compared with
50.8% for P. falciparum [8]. The parasite reservoir of P. vivax is also aided by the dormant liver
stage which can cause relapsing infection, with fast gametocyte production allowing transmis-
sion earlier in the course of the disease, and the development of multidrug resistance [9] posing
difficulties for both clinical management and malaria elimination goals.
In non-referral settings in elimination areas, the diagnostic tools currently available for
detection of P. vivax infections for case management and surveillance are microscopy and
immunochromatographic lateral-flow antigen detection in the form of “rapid diagnostic tests”
(RDTs). Reference laboratories may also offer expert microscopy and PCR. The reliability of
RDTs for diagnosing P. vivax infections, particularly at low level parasitemia, remains less than
that for P. falciparum [4,10]. While the most recent WHO RDT testing report found the high-
est performing parasite lactate-dehyrogenase (pLDH) based P. vivax RDTs were equivalent to
HRP2-based P. falciparum RDTs at parasitemias of 200/μL [11], they remain inadequately
High-Throughput LAMP for P. vivax for Malaria Elimination
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sensitive for the detection of lower level P. vivax and P. falciparum parasitemia in sub-patent
asymptomatic individuals. While microscopy and RDT provide adequate diagnostic accuracy
for case management of symptomatic patients in clinical settings, they have been shown to be
inadequate in detecting a large proportion of low density P.falciparum infections in active com-
munity surveillance [12], and for mass screening and treatment programs [13]. Studies using
RDTs specifically for detection of P. vivax in this context are yet to be performed, although
similar results could be expected given the inherently lower parasitemias associated with P.
vivax infection. Although molecular based assays such as conventional PCR are capable of
detecting very low density infections, they are not suitable for large scale community surveil-
lance due to complex procedures that do not allow provision of test results on the day of sam-
ple, expensive reagents and the requirement for specialised equipment.
Loop mediated isothermal amplification (LAMP) is a molecular diagnostic technology that
has the potential to be a readily-applicable tool in settings such as malaria elimination. LAMP
is an isothermal process that relies on the Bacillus stearothermophilus (Bst) enzyme and does
not require cyclical temperature changes [14]. As such, unlike PCR, it offers an opportunity for
field adaptation because of its low technology requirement. The output of a LAMP reaction
can be visualised as a magnesium pyrophosphate precipitate detectable by turbidimetry [14],
metal ion detectors such as calcein [15], hydroxynaphthol blue [16] and pico-green [17]. In
addition to melting curve analysis [18], LAMP end products have also been visualised using a
bioluminescent output in real time(BART) [19], a lateral flow dipstick [20], or a portable device
with a fluorescence detecting unit (realAmp) [21]. LAMP has also recently been performed on
non-instrumented nucleic acid amplification (NINA) platforms [22] improving its potential
for field application.
LAMP has been shown to detect all Plasmodium species [23] including P. knowlesi [24,25],
to be amenable to use with crudely extracted DNA from whole blood [26], and to have a limit
of detection of 5 parasites/ μL for identifying Plasmodium genus and P. falciparum [27]. Com-
mercially available Loopamp MALARIA detection kits (Eiken chemical co) using Plasmodium
genus and P. falciparum have been found to perform well in regional health facilities, but were
not capable of specifically detecting P. vivax [28,29]. Furthermore, for specific detection of P.
vivax, the three LAMP assays published to date have had low analytic sensitivity, with reported
detection limits of 100 plasmid copies/ μL for 18s rRNA target [23] (which was equivalent to
500 parasites/ μL when tested by Patel et.al [30]), 125 parasites/μL for Pvr64 target (highly con-
served repeat region in P. vivax genome) [30] and 100 copies/ μL for alpha-tubulin target [31].
Here we describe the development and validation of a novel P. vivax specific LAMP assay
targeting mitochondrial DNA in a high-throughput, colourimetric platform. Its performance
was compared to PCR and microscopy in a district hospital, non reference laboratory setting.
Methods
The clinical samples used retrospectively in this study to validate the P. vivax specific primers
were obtained with ethics approval granted by the Malaysian Medical Research Ethics Com-
mittee, Menzies School of Health Research, Australia, and London School of Hygiene and
Tropical Medicine, UK.
Parasite samples used for validating primers and limit of detection (LOD)
Primers were tested against parasite DNA from well characterised parasite lines and clinical
samples of P. falciparum (3D7), P. vivax, P.malariae, P. ovale spp. and P. knowlesi for cross-
reactivity and LOD.
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In order to determine the analytical sensitivity of the HtLAMP-Pv, a two-fold dilution series
of a P. vivax DNA sample beginning at a starting parasitemia of 90,000 parasites/ μL (as deter-
mined by quantitative PCR) was evaluated in duplicate. HtLAMP-Pv performance was com-
pared with that of previously published P. vivax primers [23,30] in the HtLAMP platform. In
addition, a sample of starting parasitemia of 2000 parasites/ μL (as determined by expert
microscopy) was serially diluted in 50% haematocrit uninfected blood. DNA from each dilu-
tion was extracted using Qiagen blood kit and tested in duplicate using the HtLAMP-Pv assay.
Comparison between HtLAMP-Pv and RDT
The limit of detection of the HtLAMP-Pv assay was compared with the SD Bioline Pf/Pan
RDT (Alere Standard Diagnostics). This RDT detects P. falciparum histidine-rich protein II
(HRP-II) and Plasmodium lactate dehydrogenase (pLDH) with a reported sensitivity of 100%
at 200 parasites/μL [11], microscopy and quantitative PCR on a blood sample obtained from a
P. vivax blood stage clinical trial (ACTRN12614000930684) participant. Informed consent was
obtained as per the approval of the QIMR Berghofer HREC. Briefly, a wild type P. vivax bank
was produced using blood collected from a patient, who had returned to Australia from a
malaria endemic country with PCR-proven P. vivaxmalaria infection, prior to treatment with
artemether-lumefantrine. The clinical trial was performed as described [32] and a 2 ml EDTA-
blood sample was collected from the clinical trial participant at peak parasitemia prior to com-
mencement of antimalarial treatment. This sample was serially diluted in 50% haematocrit
blood and each dilution was subjected to an LDH ELISA assay, thick film blood smear for
expert microscopy, an SD Bioline Pf/Pan RDT (Alere Standard Diagnostics) and 4 x 5 μL filter
paper (whatman) blood spots. The filter paper blood spots and the remaining whole blood,
which had been stored at -20°C, was extracted in 10 μL and 50 μL volumes using modified che-
lex-saponin based DNA extraction protocols as described below. The extracted DNA was
stored at -20°C until performance of the HtLAMP-Pv assay.
Diagnostic accuracy and field testing of HtLAMP-Pv
The sensitivity and specificity of the P. vivaxHtLAMP was tested retrospectively on clinical
samples from patients enrolled in a randomised controlled trial and case-control study per-
formed in Sabah, Malaysia commencing in December 2012 as outlined by Grigg et al. [33].
Briefly, samples were collected from microscopy positive, symptomatic patients presenting as
outpatients to Kota Marudu District Hospital and asymptomatic, microscopy negative, com-
munity controls as a result of reactive active case detection from within the village of a case
patient from Kota Marudu district, Sabah. These were stored as 20 μL filter paper (Whatman)
blood spots. A subset of 149 microscopy positive samples and 112 microscopy negative samples
were used to compare the performance of the P. vivaxHtLAMP (HtLAMP-Pv), with micros-
copy and PCR. DNA extraction of the filter paper samples from symptomatic patients and
HtLAMP-Pv were performed in the Kota Marudu district hospital laboratory, with no standing
molecular diagnostic capability, using a plastic bucket adapted into a water bath, a centrifuge
and a portable spectrophotometer. Two local staff members were trained in the process of per-
forming and interpreting the assay as part of its evaluation.
DNA extraction
The P.vivax DNA used for the analysis of sensitivity was extracted from whole blood samples
as per Qiagen manufacturing protocol (QIAamp DNA mini kit) with some modifications.
Briefly, 500 μL of packed red cell blood sample was mixed with 500 μL of PBS. To an aliquot of
500 μL of this mix, 400 μL of Qiagen AL Lysis buffer and 40 μL of Qiagen proteinase K were
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PLOS Neglected Tropical Diseases | DOI:10.1371/journal.pntd.0004443 February 12, 2016 4 / 16
added. After incubation at 56°C for 10 minutes, 400 μL of 100% ethanol was added, mixed then
loaded into a spin column for centrifugation at 8,000 rpm for 1 min. The spin column was then
washed once with 650 μL of AW1 and then AW2 spinning each wash at 8,000 rpm for 1 min
followed by a dry spin after the AW2 wash at 13,000 rpm for 1 minute. Nucleic acid extract
were eluted in 100 μL of elution buffer and stored at -20°C until LAMP reactions were
performed.
P. vivax DNA from the Kota Marudu clinical filter spot samples from symptomatic patients
was extracted using an established chelex protocol [34] with incubations shortened to improve
turnaround time. Briefly, 6 mm filter paper punch samples were incubated in PBS containing
0.5% saponin for 2 hours at 37°C, before being centrifuged, washed in PBS, heated at 98°C for
30 minutes in 150 μL 6% chelex and centrifuged at 4,000 rpm for 3 minutes. The resultant
100 μL DNA supernatant was then stored at -20°C until analysis by PCR and LAMP.
Red cell pellet samples from asymptomatic individuals were extracted using a different che-
lex protocol. Briefly, 1 ml of non-ionised water was incubated with 10 μL of whole blood for
15–30 minutes at room temperature, followed by centrifugation at 10,000–15,000 x g for 3
minutes. After discarding supernatant, 200 μL of 5% chelex was added, vortexed for 5–10 sec-
onds, incubated at 55°C for 30–90 minutes and vortexed again for 5–10 seconds. The sample
was then heated for 10 minutes at 100°C, vortexed for 5–10 seconds and centrifuged for 3 min-
utes at 10,000–15,000 x g. The DNA supernatant was placed in a sterile microfuge tube for stor-
age at -20°C.
Whole blood samples, for the comparative study with RDTs, were extracted using a chelex-
based DNA extraction methodology [35] modified by the addition of saponin. Briefly, 10 μL of
whole blood was mixed with either 200 μL of 0.5% saponin and incubated at 37°C for 30 min-
utes. Samples were then centrifuged, supernatant discarded and pellet heated at 98°C in 150 μL
of 6% chelex for 30 minutes. The resultant supernatant was stored at -20°C. The process was
also performed on 50 μL of whole blood.
Positive control plasmid
In order to establish specificity of the P. vivax LAMP primers, a plasmid containing P. vivax
cox1 gene was constructed. The target region of the gene was amplified using COX1 specific
PCR primers. Reactions were performed in 20 μL total volume containing 1X NH4 buffer,
2 mMMgCl2, 200 μM dNTPs, 200 μM primer mix and 0.5 U Taq polymerase (Bioline). The
~500 bp PCR product was visualised following agarose gel electrophoresis. The PCR product
was purified using a commercial kit (Roche) and TA cloned using pGEM-T easy as per manu-
facturer instructions. Recombinant E. coli were identified by blue-white colour selection. Pres-
ence of the P. vivax cox1 gene within the plasmid was confirmed by PCR and Sanger
sequencing.
Estimation of the number of mitochondrial cox1 genes in the P. vivax
genome
Copy number of the pvcox1 gene in the P. vivax genome was estimated by quantitative real
time PCR SYBR green PCR assay using the Light Cycler 96 (Roche). Two single copy genes
coding for P. vivax mdr1 (GenBank Acc No. AY618622.1) and P. vivax aldolase (GenBank Acc
No. AF247063) were used as reference genes to estimate the pvcox1 copy number. PCR reac-
tions were set up in triplicates using the Roche Fast Start Essential DNA Green Master Mix
(Cat. No. 06 402 712 001), 10 μM of each primer (Table 1) and 1 μl of each DNA (cox1 plas-
mid, mdr/aldolase plasmid, Pv gDNA) in a 12 μl reaction volume. Cycling conditions were: 950
High-Throughput LAMP for P. vivax for Malaria Elimination
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C for 3 mins; 45 cycles of 950 C 30 secs and 600 C for 1 min. This was followed by melt curve
analysis to confirm correct products were synthesised.
To assess PCR amplification efficiencies, standard curves containing five ten-fold dilutions
of two plasmids containing either pvcox 1, or pvmdr1 and pvaldolase (1:1) Suwanarusk, 2007
[36] were prepared, starting from the same initial concentration of 7.2 x10-4 ng/μl. Differences
in CT value between pvcox1 and pvmdr1/pvaldolase at each plasmid concentration was calcu-
lated and averaged to derive ΔCTcal. After confirming similar amplification efficiencies, geno-
mic DNA extracted from 5 well characterised P. vivax isolates with varying DNA
concentrations were used in the copy number assay. These samples were from patients enrolled
in a clinical trial and surveillance study, with ethics approval granted by the Malaysian Medical
Research Ethics Committee and Menzies School of Health Research, Australia, conducted in
Kota Marudu district, Sabah, Malaysia[37,38]. Mean Ct values were calculated from triplicate
and analysed using Graph Pad Prism (version 6). The pvcox1 copy number in each sample was
calculated as N = 2 ΔΔ Ct +/- SD i.e. N = 2 (CTpvmdr1-CTpvcox1)-(CTpvmdr1cal-CTpvcox1cal) as reported
in Suwanarusk, 2007 [36].
PCR
Nested PCR for P. vivax was performed as previously published [39]. Reactions were per-
formed in 20 μL total volume containing 1X buffer, 2 mMMgCl2, 200 μM dNTPs, 200 μM
primer mix (rPLU5new/rPLU6 for nest 1 and rVIV1/rVIV2 for nest 2) and 0.5 U Taq polymer-
ase (Bioline). PCR products were visualised on a 2% agarose gel.
Multiplex PCR [40] for the detection of P. falciparum, P. vivax, P.malariae and P. ovale was
performed on clinical samples from the 149 symptomatic case samples, with P. knowlesi con-
firmed using PCR as described by Imwong et al. [41]. Nested PCR, as described by Singh et al.
[42], was performed on the 112 community control samples. Quantitative PCR on the P. vivax
blood stage clinical trial sample was performed as previously described [32].
High-throughput LAMP
High throughput (HtLAMP) was performed on a 96-well standard u-bottom microtitre plate
(Sterihealth) as previously described [43]. Briefly, reactions were performed in 25 μL total vol-
ume containing 5 μL DNA, 1X buffer (20 mM Tris HCL pH 8.8, 10 mM KCl, 8 mMMgSO4,
10 mM(NH4)SO4), 1.25 mM each dNTP, 1.78 μM each FIP/ BIP, 0.8 μM each LF/ LB, 0.2 μM
each F3/ B3), 120 μM hydroxynaphthol-blue (Fluka, CAS number 63451-35-4)and 8 units Bst
polymerase (New England Biolabs, Ipswich, MA). The microtitre plate was incubated in a
waterbath at 65°C for 30 minutes before the colour change and precipitate in each well was
recorded. A blue colour change with a visible precipitate was scored as a positive result, and
purple colour without a precipitate was a negative result (Fig 1). The microtitre plate was then
read in an ELISA plate reader at 600 nm wavelength to obtain an optical density (OD) reading
Table 1. Primers used to amplify Pvmdr, aldolase and cox 1 (*Source [36]).
Gene Primer name Sequence
pv mdr* Pvmdr F 5’ CTGATACAAGTGAGG AAG AACTAC G 3’
Pvmdr R 5’ GTCCACCTGACAACTTAGATGC 3’
pv aldolase* Pvaldo F 5’ GACAGTGCCACCATCCTTACC 3’
PvaldoR 5’ CCTTCTCAACATTCTCCTTCTTTCC 3’
pv cox 1 V1V2F3 5’ GGTACTGGATGGACTTTATAT 3’
V1V2B3 5’ GGTAATGTTAATAATAGCATTACAG 3’
doi:10.1371/journal.pntd.0004443.t001
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of each well. The threshold value for a positive reaction was calculated using the mean plus two
standard deviations of the no template control (NTC) wells. A positive or negative OD reading
for each sample was then calculated using the threshold value and correlated with the visually
detected colour change. Samples that were discordant in terms of colour change and OD
threshold were deemed negative.
Statistical analysis
PCR, nested or multiplex, for the detection of P. vivax was used as the gold standard by which
the sensitivity and specificity of HtLAMP-Pv was calculated. PCR is the best established molec-
ular diagnostic tool available for the detection of Plasmodium parasites and therefore an appro-
priate choice for comparison of a new molecular diagnostic modality.
Sensitivity was estimated as the number of LAMP positives that were also PCR positive,
divided by the number of PCR positives. Specificity was estimated as the number of LAMP
negatives that were also PCR negative divided by the total number of PCR negatives.
Results
P.vivax LAMP primers
Two sets of LAMP primers (VIV1 and VIV2) targeting P. vivaxmitochondrial sequences were
designed manually. Each set of primers was tested for its ability to amplify P. vivax-specific DNA.
Fig 1. HtLAMP colour change associated with hydroxynaphtholblue (HNB). Left clear, purple
colour = negative and right cloudy, blue colour = positive.
doi:10.1371/journal.pntd.0004443.g001
Table 2. P. vivax VIV2 HtLAMP primer sequences (5’! 3’).
Primer Sequence
F3 GGTACTGGATGGACTTTATAT
B3 GGTAATGTTAATAATAGCATTACAG
LF GATAACATCTACTGCAACAGG
LB CTACTGTAATGCATCTAAGATC
FIP CCAGATACTAAAAGACCAACCCACCATTAAGTACATCACT
BIP GCTAGTATTATGTCTTCTTTCACTTAATATACCAAGTGTTAAACC
doi:10.1371/journal.pntd.0004443.t002
High-Throughput LAMP for P. vivax for Malaria Elimination
PLOS Neglected Tropical Diseases | DOI:10.1371/journal.pntd.0004443 February 12, 2016 7 / 16
However, only one set of primers (VIV2) targeting the P. vivaxmitochondrial cox1 gene (Table 2
and Fig 2), was subject to further validation as the other set failed to amplify P. vivaxDNA. The
specificity of VIV2 primers was investigated by searching for nucleotide similarity using the
BLAST algorithm at the NCBI nucleotide database (www.ncbi.nlm.nih.gov/Blast.cgi) and found
to have limited sequence identity only to other Plasmodium species. Given the conserved nature
of the mitochondrial genome and the sequence similarity across different P.vivax strains from
around the world, no evaluation of VIV2 primers on different P.vivax strains was performed.
Species-specificity of VIV2 LAMP primers
The VIV2 primer set was tested in duplicate on DNA extracts from one PCR-confirmed sample
of each of the following species: P. vivax, P. falciparum, P. knowlesi, P.malariae, P. ovale wallikeri
and P. ovale curtisi. There was amplification of P. vivax and P. knowlesiDNA but no amplifica-
tion product was detected for P. falciparum, P.malariae, P. ovale wallikeri or P. ovale curtisi.
Quantification of mitochondrial cox1 gene copy numbers in the P. vivax
genome
Using the single-copy P. vivax aldolase gene as reference, the estimated copy number of pvcox1
in five selected P. vivax samples ranged from 9.2–16.47 with a mean of 12.43 (± 1.233). Using
Fig 2. P. vivax VIV2 HtLAMP primer set superimposed on alignments of P. vivax (AY598035), P. falciparum (AJ276844) and P. knowlesi
(NC_007232) cox1 genes.
doi:10.1371/journal.pntd.0004443.g002
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the pvmdr1 gene as reference, the estimated copy number of pvcox1 ranged from 7.32–14.05
with a mean of 10.28 (± 1.182) (Fig 3).
Limit of detection of HtLAMP-Pv
Using a two-fold DNA dilution series of a clinical P. vivax sample, with a starting parasitemia
of 90,000 parasites/ μL as determined by quantitative PCR, the LOD was 1.4 parasites/ μL
(Table 3). Using the same dilutions, the LOD of P. vivax LAMP primers published by Han [23]
and Patel [30], in the HtLAMP platform was determined to be706 parasites/ μL and 176 para-
sites/ μL respectively. HtLAMP-Pv performed on the microscopy-determined P. vivax dilution
series in whole blood had an LOD of 2 parasites/ μL (Table 4).
HtLAMP-Pv vs RDT
Quantitative PCR analysis of the P. vivax blood stage clinical trial sample confirmed a peak
parasitemia of 12 parasites/ μL prior to commencement of antimalarial therapy. HtLAMP-Pv
was positive and the RDT was negative at this level of parasitemia. The limit of detection
(LOD) of the HtLAMP-Pv assay varied depending on the type and volume of sample from
which DNA was extracted. The LOD for filter paper extracted using saponin and chelex was
more than 12 parasites/ μL whereas the LOD for 10 μL and 50 μL of whole blood extracted
using saponin and chelex was 3 parasites/ μL and 1.5 parasites/ μL respectively (Table 5).
Sensitivity and specificity of HtLAMP-Pv in symptomatic patients
Of the 149 patients with microscopy-confirmed malaria from the district of Kota Marudu,
Sabah, Malaysia, 145 were confirmed by PCR: 4 samples were excluded due to lack of micros-
copy and PCR data, 56 were identified as P. knowlesi (median parasitemia 2005 parasites/ μL,
range 26–143,790), 64 as P. vivax (median parasitemia 4676 parasites/ μL, range 53–89,640), 7
as P.malariae, 17 as P. falciparum (median parasitemia 18,725 parasites/ μL, range 837–
693,922) and 1 as a mixed P knowlesi/P. vivax infection. HtLAMP-Pv was compared with mul-
tiplex PCR in these clinical samples. The sensitivity of HtLAMP-Pv for P. vivax was 95% (62/
65, 95% CI 87–99) and specificity was 55% (44/80, 95% CI 43–66) respectively compared with
multiplex PCR and 94% (59/62, 95% CI 85–98) and 53% (44/83, 95% CI 42–64) respectively
compared with expert microscopy (Table 2). The low specificity of the assay can be attributed
Fig 3. Estimated Plasmodium vivax cox1 copy number based on comparison with two single copy
genes, pv aldolase1 and pvmdr1.
doi:10.1371/journal.pntd.0004443.g003
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to cross-reactivity of the VIV2 primers with P. knowlesi, with 97% sequence homology at the
cox1 gene between P. vivax and P. knowlesi. When P. knowlesi samples were excluded from the
analysis, the specificity was 100% compared with both multiplex PCR and microscopy
(Table 6).
Sensitivity and specificity of HtLAMP-Pv in asymptomatic, reactive
active case detection community control patients
HtLAMP-Pv was compared with nested PCR for red cell pellet samples from asymptomatic,
microscopy negative community controls from the malaria endemic district of Kota Marudu,
Sabah, Malaysia. The sensitivity of HtLAMP-Pv was 71% (95% CI 29–96; 5/7) and specificity
was 93% (95% CI 87–97; 98/105) compared with PCR.
Table 3. Analytical sensitivity of HtLAMP-Pv, compared with other published P. vivax LAMP primers, using a DNA dilution series of clinical sample
with qPCR confirmed parasitemia. Each sample was tested in duplicate in the HtLAMP platform using each of the three P. vivax LAMP primer sets. The
dilution at which both duplicates were positive was the limit of detection for each of the primer sets in the HtLAMP platform (Pos* indicates dilutions at which
only one of the duplicates was positive). HtLAMP-Pv was able to detect 1.4 parasites/ μL compared with previously published P. vivax LAMP primers.
Sample Quantitative PCR (parasites/μL calculated) [23] 18s rRNA target [30] Pvr64 target HtLAMP-Pv cox1 target
1 Original 90,000 Pos Pos Pos
2 45,000 Pos Pos Pos
3 22,500 Pos Pos Pos
4 11,250 Pos Pos Pos
5 5625 Pos Pos Pos
6 2813 Pos Pos Pos
7 1406 Pos Pos Pos
8 703 Pos Pos Pos
9 352 Pos* Pos Pos
10 176 Pos Pos
11 88 Pos
12 44 Pos
13 22 Pos
14 11 Pos
15 5.5 Pos
16 2.7 Pos* Pos
17 1.4 Pos
18 0.7 Pos*
19 0.3
doi:10.1371/journal.pntd.0004443.t003
Table 4. Analytical sensitivity of HtLAMP-Pv onmicroscopy-determined whole blood P. vivax dilution
series. The limit of detection HtLAMP-Pv is 2 parasites/ μL, performed in duplicate and where both dupli-
cates were positive.
P. vivax Parasites /μL HtLAMP-Pv
2000 Pos
200 Pos
20 Pos
2 Pos
0.2 Neg
0 Neg
doi:10.1371/journal.pntd.0004443.t004
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Turnaround time of assay
The HtLAMP assay turnaround time was 1 hour after DNA extraction, 4 hours when com-
bined with whole blood chelex saponin protocol and 6 hours when combined with filter paper
rapid DNA extraction protocol.
Applicability of the assay in a non-reference laboratory in a resource
limited setting
HtLAMP-Pv testing of a total of 149 filter paper samples was performed successfully in a
regional hospital laboratory in Kota Marudu district, Sabah, Malaysia. Good workflow set up
ensured that there was no contamination despite the lack of formal molecular diagnostic infra-
structure. Locally trained staff was able to perform and interpret results of the HtLAMP-Pv
assay using only a centrifuge, pipettes, water bath and a portable spectrophotometer.
Discussion
Field-applicable diagnostic tools for the detection of Plasmodium vivax are essential compo-
nents for the malaria eradication agenda [44]. Given the widespread distribution and unique
challenges P. vivax poses compared with P. falciparum, there is a pressing need for the
Table 5. Comparingmicroscopy and RDT with the limit of detection of HtLAMP-Pv using filter paper and whole blood at 10 μL and 50 μL volumes.
0.75 parasites/ μL 1.5 parasites/ μL 3.0 parasites/ μL 6.0 parasites/ μL 12 parasites/ μL
Microscopy Neg Neg Pos Pos Pos
RDT Neg Neg Neg Neg Neg
Filter paper (5 μL) Neg Neg Neg Neg Pos
Whole blood 10 μL Neg Neg Pos Pos Pos
Whole blood 50 μL Neg Pos Pos Pos Pos
The limit of detection (LOD) of the HtLAMP-Pv assay depends on the starting sample material and the volume of blood extracted. LOD threshold was
determined by the presence of 2 positive duplicate tests (ie: 4 positive results) at a particular parasitemia. The LOD for a 5 μL ﬁlter paper blood spot
extracted using a chelex-saponin protocol was more than 12 parasites/ μL. The LOD for 10 μL of whole blood extracted using a chelex-saponin protocol
was 3 parasites/ μL compared with 50 μL of whole blood which was 1.5 parasites/ μL.
doi:10.1371/journal.pntd.0004443.t005
Table 6. Sensitivity and specificity of HtLAMP-Pv for P. vivax in symptomatic patients in Sabah with P.
falciparum, P. vivax and P. knowlesi. 149 filter paper samples were tested by HtLAMP-Pv; 4 samples were
excluded due to a lack of PCR and microscopy data. Among the 145 samples, PCR confirmation of species
was as follows: n = 64 P. vivax n = 56 P. knowlesi, n = 17 P. falciparum, n = 7 P.malariae and n = 1 mixed P.
vivax/P. knowlesi infection.
Sensitivity Speciﬁcity
HtLAMP-Pv compared with multiplex PCR 62/65(95%) 44/80 (55%)
(95% CI 87–99) (95% CI 43–66)
HtLAMP-Pv compared with multiplex PCR excluding Pk samples 62/65(95%) 24/24 (100%) (
(95% CI 87–99) 95% CI 87–99)
HtLAMP-Pv compared with microscopy 59/62 (95%) 44/83 (53%)
(95% CI 85–98) (95% CI 42–64)
HtLAMP-Pv compared with microscopy excluding Pk samples 59/62 (95%) 18/18 (100%)
(95% CI 85–98) (95% CI 81–100)
Multiplex PCR compared with microscopy 60/65 (92%) 78/80 (98%)
(95% CI 83–97) (95% CI 91–99)
doi:10.1371/journal.pntd.0004443.t006
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development of species- specific molecular diagnostic tools. LAMP is a molecular diagnostic
tool which holds much promise in terms of its ability to be deployed in non-referral laboratory
settings, given its simplicity and rapid assay turnaround time, ability to be performed on
crudely extracted DNA from both whole blood and filter paper and lack of expensive equip-
ment. The colourimetric, 96 well microtitre plate-based platform for performing LAMP
(HtLAMP) for the detection of Plasmodium parasites, as previously described [43], increases
the throughput of the LAMP using minimal equipment. The objective of this paper was to
develop and validate a P. vivax specific HtLAMP assay on this platform with good diagnostic
accuracy.
The 6-kb mitochondrial genome of the genus Plasmodium encodes three mitochondrial
proteins- cytochrome B (cytb) and subunit 1 and 3 of cytochrome c oxidase (cox1 and cox3),
and is estimated to be present in relatively high copy number. The complete mitochondrial
genome of P. vivax (Genbank AY598035) has been shown to be closely related to P. knowlesi
[45]. Previously published standard PCR primers for P. vivax targeting cox1 have shown 100%
sensitivity and specificity [46], but were not evaluated against P. knowlesi. LAMP primers tar-
geting mitochondrial sequences for the detection of P. genus and P. falciparum demonstrated
an analytical sensitivity of 5 parasites/ μL [27] suggesting that mitochondrial DNA offers an
attractive target, presumably due to increased copy number of mitochondrial targets within
cells. Recent estimates of genomic sequence coverage have shown that the P. falciparum
genome contains ~20 copies/cell of the mitochondrial genome [47].
This HtLAMP-Pv assay targeting the conserved cox1 gene demonstrated excellent analytic
sensitivity, being able to detect 1.4 parasites/ μL. This is the lowest LOD so far achieved for a
published P. vivax–specific LAMP assay. The estimated copy number for cox1 in P. vivax is
approximately 11 copies/ cell. Therefore, it is likely that the sensitivity of the HtLAMP-Pv
assay is a reflection of the increased number of mitochondrial targets per cell. Previously pub-
lished P. vivax LAMP primers, which targeted non-mitochondrial genes, when used in the
HtLAMP platform had limits of detection of 706 parasites/ μL and 176 parasites/ μL which cor-
related well with published limits of detection of 125–500 parasites/ μL for these P. vivax prim-
ers sets [30].
The pkcox1 gene of P. knowlesi exhibits 97% sequence identity with pvcox1 at the nucleotide
level, and thus the cross-reactivity of the VIV2 primers between these two species was expected.
However, there was no cross-reactivity with P. falciparum (87% sequence identity), P. ovale
wallikeri (92%), P. ovale curtisi (92%) or P.malariae (93%).
Validation of the HtLAMP-Pv in clinical samples of symptomatic patients with vivax, fal-
ciparum and knowlesi malaria demonstrated sensitivity for P. vivax of 94–95% and a specificity
of 53–55% compared with microscopy and multiplex PCR respectively. The poor specificity
however was a reflection of the cross-reactivity with P. knowlesi. When P. knowlesi samples
were excluded from the analysis, the specificity of the HtLAMP-Pv assay improved to 100%,
compared with both multiplex PCR and microscopy.
While this cross-reactivity appears to be a limitation of this HtLAMP-Pv assay, P. knowlesi
malaria is uncommon or absent in most areas of P. vivax endemicity, so this would be an
important consideration only in Malaysia, where P. knowlesi predominates [48] and in the
other countries in south-east Asia where P. knowlesi human infection has been documented
[49]. In terms of treatment, both P. vivax and P. knowlesi respond to artemisinin-based combi-
nation therapy (ACT) [50]. However, in elimination programmes utilising primaquine for rad-
ical cure of P. vivaxmalaria, there is a potential risk of inappropriate use of this potentially
haemolytic drug in people with P. knowlesi infections. This is a problem localised to Southeast
Asia, and would not pose a problem for LAMP-based detection and radical treatment of P.
vivax for malaria elimination elsewhere.
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The HtLAMP-Pv assay was also evaluated in a limited sample set of asymptomatic, micros-
copy negative, community control patients enrolled from the same village as a case patient, as a
result of reactive active case detection. Although the LOD of HtLAMP-Pv appears to be 1.4
parasites/ μL, in this sample set its sensitivity was only 71%. This may be due to the very low
parasitemias in these 7 PCR positive samples or variability due to stochastic effects at such low
parasitemias. Therefore further validation in a larger sample set is required to confirm the sen-
sitivity of HtLAMP-Pv in this population in order to evaluate the potential role for
HtLAMP-Pv as a diagnostic tool in malaria elimination settings.
HtLAMP-Pv showed significantly better sensitivity than the SD Bioline Pf/Pan RDT at low
parasitemia. RDTs were negative in the serially diluted samples at 12 parasites/ μL.
HtLAMP-Pv was positive at this level. The analytical sensitivity of the assay varied depending
on whether filter paper samples or whole blood was used irrespective of the chelex-saponin
DNA extraction protocol used. This may have important implications for choosing the type of
sample collected in addition to choosing the appropriate diagnostic tool for surveillance or
screening policy and protocols for malaria elimination programs.
In this study we also demonstrated that HtLAMP-Pv performed well in the 96-well microti-
tre plate platform for increasing the throughput of the assay in a non-referral laboratory in a
district hospital in Sabah, Malaysia. DNA extraction was performed in the non-referral labora-
tory using a chelex protocol on filter paper blood spots and the HtLAMP-Pv assay was able to
process these samples in a simple water-bath within one hour from time of DNA extraction.
Positive and negative results were readily identified by two locally trained staff by visual inspec-
tion of the colour change. Optical densitometry readings at 600 nm in portable photospectrom-
eter were used to provide objective confirmation of the visually detected results. As such the
validation of this HtLAMP-Pv assay in a rural district laboratory setting confirms the potential
it has as a field-applicable molecular diagnostic tool. Furthermore, the process of assay valida-
tion using the combination of visual and optical densitometry values has previously shown that
the visually detectable colour change was reliable for determining both positive and negative
results [43]. Therefore while the photospectrometer offers objective confirmation, it is not an
essential component of the assay.
Some of the limitations to this platform pertain to DNA extraction. Firstly, in order to
maintain cost effectiveness of the assay, modified chelex-based protocols were used for whole
blood and filter paper extractions. Although these multi-step DNA extraction processes, which
relied on a centrifuge, were performed adequately in a resource limited setting, further simplifi-
cation of DNA extraction would enhance the feasibility of the HtLAMP-Pv assay. It would also
allow a greater number of samples to be processed, as might be required for mass surveillance
for malaria elimination, thereby making full use of the high throughput aspect of the HtLAMP
platform. Secondly, while equivalent small volumes of blood on filter paper and whole blood
have shown whole blood to produce better analytical sensitivity in the HtLAMP platform [43],
the limit of detection of HtLAMP-Pv using larger volumes of blood on filter paper is yet to be
established.
In conclusion, this study outlines the development and validation of a novel P. vivax-specific
LAMP assay which combines a low limit of detection with a high throughput, colourimetric,
field applicable molecular diagnostic assay. As such, this HtLAMP assay holds much promise
as a diagnostic tool to support malaria elimination efforts in resource-limited P. vivax endemic
settings.
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